Optimization of transcriptional regulatory elements for constructing plasmid vectors.

In studies regarding both gene therapy and gene function, transgene expression by plasmid vectors benefits from the use of transcriptional regulatory elements which permit high-level gene expression. Therefore, with respect to transgene (luciferase) expression activity both in vitro (using HeLa, HepG2, and ECV304 cells) and in vivo (mouse liver and skeletal muscle), we investigated the effective combination of commonly-used regulatory elements, such as the promoter/enhancer, intron, and polyadenylation signal (P(A)) sequence by constructing a series of plasmids that differed only in the particular sequence element being evaluated. Of the several promoter/enhancers that were tested, hybrid CA promoter/enhancer containing human cytomegalovirus immediate-early 1 gene (CMV) enhancer and chicken beta-actin promoter with the beta-actin intron sequence, and the improved CMV promoter/enhancer containing the largest intron of CMV (intron A) produced the highest levels of expression both in vitro and in vivo. P(A) sequences were found to have significant effects on transgene expression. The effect of a multiple enhancer was also examined. Optimized plasmids of this study were pCASL3 (composed of CMV enhancer, beta-actin promoter, beta-actin intron, Simian virus (SV40) P(A) sequence and SV40 enhancer) and pCMVSL3 (composed of CMV enhancer, CMV promoter, intron A, SV40 P(A) sequence and SV40 enhancer). These comparative analyses could provide a systematic reference for the development of vector construction for gene therapy, vaccine development, and gene transfer experiments.

[1]  I. Jones,et al.  Analyses of alternative poly(A) signals for use in baculovirus expression vectors. , 1993, Virology.

[2]  R. Jaenisch,et al.  A generic intron increases gene expression in transgenic mice , 1991, Molecular and cellular biology.

[3]  D. Nettelbeck,et al.  Cell type specificity of the human endoglin promoter. , 1999, Gene.

[4]  Robert Tjian,et al.  Transcriptional selectivity of viral genes in mammalian cells , 1986, Cell.

[5]  C. Gorman,et al.  Intervening sequences increase efficiency of RNA 3' processing and accumulation of cytoplasmic RNA. , 1990, Nucleic acids research.

[6]  Dexi Liu,et al.  Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA , 1999, Gene Therapy.

[7]  Tomoko Nakanishi,et al.  ‘Green mice’ as a source of ubiquitous green cells , 1997, FEBS letters.

[8]  J. Marshall,et al.  Optimization of plasmid vectors for high-level expression in lung epithelial cells. , 1997, Human gene therapy.

[9]  B. Seliger,et al.  Gene transfer into brain tumor cell lines: Reporter gene expression using various cellular and viral promoters , 1990, Journal of neuroscience research.

[10]  H. Ertl,et al.  Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses , 1995, Journal of virology.

[11]  L. Wang,et al.  Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer. , 1996, Gene therapy.

[12]  A. Rundell,et al.  Gene therapy by intramuscular injection of plasmid DNA: studies on firefly luciferase gene expression in mice. , 1993, Human gene therapy.

[13]  J. Kopchick,et al.  Growth hormone gene expression in eukaryotic cells directed by the Rous sarcoma virus long terminal repeat or cytomegalovirus immediate-early promoter. , 1985, Gene.

[14]  P. Noguchi,et al.  The safety of retroviral vectors. , 1993, Human gene therapy.

[15]  K. Barnhart,et al.  An improved plasmid DNA expression vector for direct injection into skeletal muscle. , 1996, Human gene therapy.

[16]  M. Kay,et al.  A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. , 1999, Human gene therapy.

[17]  N. Proudfoot.  How RNA polymerase II terminates transcription in higher eukaryotes. , 1989, Trends in biochemical sciences.

[18]  B. Demeneix,et al.  Direct gene transfer into skeletal muscle in vivo: factors affecting efficiency of transfer and stability of expression. , 1993, Human gene therapy.

[19]  Yamamura Ken-ichi,et al.  Efficient selection for high-expression transfectants with a novel eukaryotic vector , 1991 .

[20]  M. Montoya-Zavala,et al.  A comparison of bovine growth-hormone gene expression in mouse L cells directed by the Moloney murine-leukemia virus long terminal repeat, simian virus-40 early promoter or cytomegalovirus immediate-early promoter. , 1988, Gene.

[21]  N. Haigwood,et al.  Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells. , 1991, Nucleic acids research.

[22]  J. Northrop,et al.  Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[23]  K. Ponder,et al.  Evaluation of relative promoter strength in primary hepatocytes using optimized lipofection. , 1991, Human gene therapy.

[24]  S. Rose,et al.  In vitro polyadenylation is stimulated by the presence of an upstream intron. , 1990, Genes & development.

[25]  M. Jaroszeski,et al.  Electrically mediated plasmid DNA delivery to hepatocellular carcinomas in vivo , 2000, Gene Therapy.

[26]  M K Foecking,et al.  Powerful and versatile enhancer-promoter unit for mammalian expression vectors. , 1986, Gene.

[27]  J. Miyazaki,et al.  A composite CMV-IE enhancer/beta-actin promoter is ubiquitously expressed in mouse cutaneous epithelium. , 1998, Experimental cell research.

[28]  D. Liu,et al.  Hydrodynamics-based gene delivery. , 2001, Current opinion in molecular therapeutics.

[29]  N. Yang,et al.  In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[30]  H. Niwa,et al.  Efficient selection for high-expression transfectants with a novel eukaryotic vector. , 1991, Gene.